Thanks for the excellent feedback and questions regarding my presentation at ESC 2019 in Paris (Sept. 3rd), entitled “HSP25 Immunotherapy Post-Menopause is Superior to Estradiol in Targeting Atherosclerosis”. There is a real opportunity for the development of HSP27 immune-facilitated therapeutics for the reduction of both cholesterol and inflammation – particularly for post-menopausal women who are at increased risk of cardiovascular events. Stay tuned for new developments in our HSP27 vaccination pipeline.
